Evaluation of a clinical scoring system and directed laboratory testing for respiratory virus infection in hematopoietic stem cell transplant recipients

P.E. Ferguson, N.M. Gilroy, T.P. Sloots, M.D. Nissen, D.E. Dwyer, T.C. Sorrell. Evaluation of a clinical scoring system and directed laboratory testing for respiratory virus infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis 2011: 13: 448–455. All rights reserved

Abstract: A simple clinical screening (CS) tool for respiratory virus (RV) infection was introduced and evaluated in a single hematology ward, as part of a strategy to reduce nosocomial RV infection. Up to 6 clinical symptoms or signs were scored and a predefined threshold score of ≥2 prompted paired nose/throat swab (NTS) collection for RV testing. The criterion standard for RV infection was positive immunofluorescence (IF) or polymerase chain reaction (PCR) for 7 and 15 viruses, respectively. The tool was shown to be most beneficial at excluding infection at a threshold score of 1 (negative predictive value [NPV] 89%, [95% confidence interval 78–96%], sensitivity 85% [70–94%], specificity 35% [27–43%]), compared with a score of 2 (NPV 85% [76–91%], sensitivity 63% [46–77%], specificity 57% [48–65%]) at a prevalence of 22%. The tool’s ability to diagnose infection was limited (positive predictive value 27% and 29% at thresholds 1 and 2). The sensitivity of IF compared with PCR was 45% for the 7 viruses common to both, and 23% for the extended virus panel detected by PCR. An algorithm incorporating CS, paired NTS collection at a threshold of 1 symptom or sign, and sensitive testing including PCR can guide infection control measures in hospitalized hematopoietic stem cell transplant recipients.

Nosocomial respiratory virus (RV) infections after hematopoietic stem cell transplantation (HSCT) are an avoidable complication with severe clinical outcomes. For example, pneumonia has been reported in up to 75% of HSCT recipients acquiring parainfluenza virus (PIV) nosocomially, with an associated mortality of 47% (1). Nosocomial RV outbreaks have been reported in multiple HSCT units (1–4), with 8 outbreaks in 13 European centers over 10 years; in 6, transplant programs were halted or closed in order to contain these infections (5).

Recommended methods to prevent nosocomial RV infection include a daily checklist for the presence of signs and symptoms of RV infection in patients beginning on the day of admission (6), placing all patients with respiratory symptoms in isolation and using respiratory and contact precautions when entering the room, excluding symptomatic staff or visitors from the unit, and deploying staff with a respiratory illness to non-patient areas (6, 7). Isolation precautions can be modified when the etiology of the illness is known (7). Although recommended, the diagnostic accuracy of using a daily checklist to prompt viral testing and infection control measures has not been assessed.

In this study, we developed a clinical case definition for RV infection based on scoring a suite of signs and symptoms of respiratory infection. A threshold score of 2 or more triggered the collection of respiratory tract specimens for viral diagnosis. The diagnostic accuracy of the case definition was evaluated in adult HSCT recipients.
Methods

All patients admitted to the hematology ward, Westmead Hospital (a university teaching hospital) in Sydney, Australia, between July 1, 2005, and September 30, 2007, were eligible for clinical screening (CS) and per-protocol testing for RV infection. This ward manages general hematology and HSCT patients, and performs 40–55 allogeneic and 15–25 autologous HSCTs annually on patients aged 16 years and above. Approval for the study was granted by the Sydney West Area Health Service Ethics Committee.

A CS score was derived from a checklist of 6 features: cough; fever >38°C in the last 24 h; sneezing, runny nose, or nasal stuffiness; shortness of breath; oxygen saturation <95% on room air; and crackles on chest examination documented by clinician in the patient record. One point was assigned to each positive finding. Nurses were requested to perform the screen daily, and enter the CS score into a log located in the bedside chart. Paired nose and throat swabs (NTS) for viral testing were recommended for patients with scores ≥ 2.

The screening tool was piloted from April 2005. Hematology nurses were educated by the researcher (P. E. F.), the nurse educator, and senior nursing staff on the use of the screening tool, sample collection techniques, and transport of swabs to the laboratory. Screening logs were placed in the patient’s bedside charts on admission.

Clinical characteristics of episodes of respiratory illness were ascertained prospectively by direct questioning of patients and caregivers by the researcher, and observations of temperature, oxygen saturation, and physical examination findings provided by treating clinicians in the case notes, and laboratory and radiology results in electronic hospital databases. Demographic data and HSCT type and date were retrieved.

The following definitions were used:

Upper respiratory tract infection (URTI): Rhinorrhea, sneezing, cough, coryza, with or without fever, with a normal chest examination and absence of pulmonary infiltrates on radiological imaging (chest x-ray or computed tomography).

Viral URTI: URTI with detection of RV from URT secretions collected by NTS (8–11).

Lower respiratory tract infection (LRTI, or pneumonia): Fever and hypoxia (oxygen saturations <95% on room air) or pulmonary infiltrates on radiological imaging (chest x-ray or computed tomography).

Viral LRTI: LRTI with the detection of RV in bronchoalveolar lavage (BAL) specimen (bronchoscopic or non-bronchoscopic), endotracheal aspirate, or URT secretions (8–10).

Upper and lower respiratory tract infection (U&LRTI): LRTI with concurrent rhinorrhea, sneezing, or coryza.

Viral U&LRTI: U&LRTI with detection of RV in BAL (bronchoscopic or non-bronchoscopic), endotracheal aspirate, or URT secretions (8–10).

Combined NTS were collected using sterile swabs moistened with viral transport medium (Copan Diagnostics, Corona, California, USA). BAL was performed on patients with adequate respiratory reserve at the discretion of hematology and respiratory physicians. Intubated and ventilated patients frequently had BAL or non-bronchoscopic–BAL samples collected during intubation.

Initial virological testing was performed in the Respiratory Virology Laboratory of the Centre for Infectious Diseases and Microbiology Laboratory Services, the Institute of Clinical Pathology and Medical Research, Westmead Hospital. Samples were processed for indirect immunofluorescence (IF) using monoclonal antibodies (Chemicon Inc., Temecula, California, USA) against influenza A and B, PIV 1–3, respiratory syncytial virus (RSV), and adenovirus (ADV). Human metapneumovirus antisera for IF (D3DFA, Diagnostic Hybrids, Athens, Ohio, USA) were available from November 2006. IF-negative NTS samples and all BAL samples were cultured for viruses in monkey kidney cell lines (LLC-MK2/BGM) and human embryonic lung fibroblasts (MRC5). Cultures were observed twice weekly (days 1–21) for cytopathic effect. IF tests were performed during normal working hours, with results available the same day for samples reaching the laboratory by 2 PM.

Residual fluid from clinical samples was frozen (–30°C). An aliquot was subsequently collected and stored at −80°C until transferred to the Queensland Paediatric Infectious Diseases Laboratory for polymerase chain reaction (PCR) for PIV 1–3; influenza A and B; RSV; human metapneumovirus (12, 13); ADV; rhinoviruses; coronaviruses OC43, 229E, NL63, and HKU1 (14, 15); polyoma-viruses WU and KI (16, 17); and human bocavirus (18).

The number of respiratory tract infection (RTI) episodes in HSCT recipients was determined by review of all clinical data. To confirm the validity of the CS score, a maximum possible (MP) score was calculated by reviewing the clinical information obtained on the same day that the CS score was logged. This information was gathered prospectively, with the MP score tallied retrospectively without knowledge of viral test results.

Statistical analysis was performed using SPSS version 15.0 and DAG_Stat (19). Medians were reported with the 25th and 75th interquartile values and compared using the Wilcoxon signed rank test. Chi-squared tests were used to compare proportions. Performance of the CS score and MP score was calculated using the k measurement of agreement. Diagnostic accuracy was assessed using sensitivity, specificity, positive, and negative predictive values (NPV) and likelihood ratios with corresponding 95% confidence intervals (95% CI). The CS score was compared with
combined IF and PCR testing as the criterion standard, and IF testing with PCR as the criterion standard. Two-tailed \( P \) values are reported.

### Results

A total of 1181 respiratory specimens (1078 NTS, 100 BAL samples, and 3 sputa) were collected over the 3-year study period from 377 patients (183 HSCT and 194 general hematology patients). HSCT recipients were predominantly male (123/183, 67%) with a median age at first sampling of 46 years (25th quartile 34, 75th quartile 55). A median of 3 NTS (1, 5) was collected from each HSCT recipient.

The screening protocol was assessed in NTS specimens collected from HSCT patients on the hematologic ward (498/1181 samples, 42.2%): 302 (60.6%) from allogeneic recipients, 71 (14.3%) from autologous recipients, and 125 (25.1%) specimens from patients scheduled to receive HSCT within 7 days. A CS score was recorded concurrently with 36.9% (184/498) of samples, of which 87 (17.5%) had no score recorded (Table 1). Both IF and PCR were performed on 448 of 498 (90%) NTS samples, IF alone on 39 (7.8%), PCR alone on 10 (2%), and neither test on 1 sample. PCR was not performed on 40 (8.0%) samples owing to an insufficient residual sample volume or sample loss before storage.

There was moderate agreement between CS and MP scores (Cohen’s \( \kappa = 0.59 \) [0.48–0.70], \( P < 0.0001 \), confirming the validity of the CS score. Both scores placed a patient in the same category to trigger RV testing (or not) for 146/184 (79.3%) samples.

A higher proportion of samples from HSCT recipients with a clinical score \( \geq 2 \) had laboratory confirmation of RVs (25/87, 28.7%) compared with those having scores of 0–1 (15/97, 15.5%) or no score recorded (54/314, 17.2%) (Table 1, \( P = 0.03 \)). RVs were detected twice as often in patients with a score \( \geq 2 \) as those with a score of 0–1 (odds ratio [OR] = 2.15, 95% CI 1.05–4.42, \( P = 0.04 \)). Median CS scores were highest during episodes of LRTI and U&LRTI (Table 2, \( P = 0.003 \), and in RV-positive episodes (\( P = 0.02 \)).

The sensitivity and specificity of the CS score in samples from HSCT recipients using a threshold of 2 were 62.5% (45.8–77.3%) and 56.9% (48.4–65.2%), respectively (Table 3). Using a threshold of 1, the corresponding values were 85.0% (70.2–94.3%) and 34.7% (27.0–43.1%). Results were similar in patients sampled during the admission for HSCT. The diagnostic accuracy was comparable during the high influenza/RSV winter season in Australia (June–September) and the remainder of the year (data not shown). The post-test probability of RV infection in HSCT recipients was calculated for varying prevalence rates (Table 4).

Compared with the observed prevalence of 22%, a score \( \geq 2 \) increased probability of infection to 29% (23–35%), and a score 0–1 reduced this probability to 15% (11–22%). The corresponding post-test probabilities using a threshold score \( \geq 1 \) were 26% (23–30%) and 11% (5–20%).

The diagnostic accuracy of viral testing procedures was calculated from 1035 respiratory samples from all hematology patients tested by both IF and PCR (87.6% of all 1181 samples). The sensitivity and specificity of IF alone compared with combined IF and PCR was 36.2% and 100%, respectively. The sensitivity of IF compared with PCR alone was 22.4% with a specificity of 96.2%. The sensitivity and specificity of IF for each virus compared with PCR alone are shown in Table 5.

One or more RVs were detected either by IF or PCR in 205 (17.2%) samples collected from 60 HSCT and 35 general hematology patients. IF gave a positive result in 8.5% (59/698) and PCR in 18.0% (115/640) samples from HSCT recipients (OR 2.37, 95% CI 1.70–3.32, \( P < 0.0001 \)). A total of 107 RV infections were detected: 84 episodes in HSCT recipients (including 12 with \( >1 \) RV) and 23 episodes in general hematology patients (including 3 with \( 2 \) RVs). Nosocomial acquisition, with onset after 4 or more days of hospitalization, occurred in 24 of 84 (28.6%) episodes in HSCT recipients, with an incidence of 5.8% (24/412 admissions). Seven episodes in HSCT recipients were fatal, with LRTI the principle cause of death in 5 episodes. All deaths from LRTI followed nosocomial RV infection.

NTS collected during episodes of URTI were more likely to have RV detected by IF or PCR than those during LRTI episodes (41/117, 35%, and 46/194, 23.7%, respectively, \( P = 0.03 \), OR 1.48, 95% CI 1.04–2.10). During episodes of LRTI, the proportion of samples with RV detected was similar for NTS and BAL specimens (46/194, 23.7%, and 11/40, 27.5%, respectively, \( P = 0.6 \)).

### Table 1

| N samples (n, % positive) | Score 0–1 | Score \( \geq 2 \) | \( P^* \) |
|---------------------------|-----------|----------------|---------|
| All samples               | 317 (54, 17.2) | 97 (15, 15.5) | 87 (25, 28.7) | 0.03 |
| All URTI samples          | 197 (50, 25.4) | 53 (12, 22.6) | 83 (24, 28.9) | 0.7 |
| URTI samples              | 56 (17, 30.4) | 22 (6, 22.7) | 19 (6, 31.6) | 0.8 |
| LRTI samples              | 99 (19, 19.2) | 26 (6, 23.1) | 59 (14, 23.7) | 0.8 |
| U&LRTI samples            | 42 (14, 33.3) | 5 (2, 4.0) | 5 (4, 80) | 0.1 |

*Test of significance is the chi-squared test.

URTI, upper respiratory tract infection; LRTI, lower respiratory tract infection; U&LRTI, upper and lower respiratory tract infection.
Following the introduction of the CS tool, collection of NTS from all hematology patients increased 4-fold (293 in years 2002–2004, 1220 in years 2005–2007, $P < 0.0001$).

**Discussion**

This is the first study to our knowledge to confirm the validity and value of using a simple clinical score to trigger microbiological testing for RV infections in hematology or HSCT patients. Daily CS of HSCT recipients for symptoms or signs of viral URTI or LRTI has been recommended previously (6), but guidelines for when sampling and testing should be performed have not been developed.

The CS tool was shown to be the most useful at detecting patients without an RV infection, and limited in its ability to diagnose those with such an infection. Such a tool is beneficial to stratify an approach to testing for readily transmissible organisms in a highly vulnerable patient setting. It

| Clinical screen score | All samples | Virus-positive RTI samples | Virus-negative RTI samples | $P^*$ |
|-----------------------|-------------|----------------------------|---------------------------|-------|
| All episodes RTI      | 2.0 (1.0, 2.0) |                            |                           |       |
| URTI                  | 1.0 (1.0, 2.0) |                            |                           | 0.003 |
| LRTI                  | 2.0 (1.0, 2.0) |                            |                           |       |
| U&LRTI                | 2.0 (0.2, 0.2) |                            |                           |       |
| All episodes RTI      | 2.0 (1.0, 2.0) | 1.0 (0.2, 0.2)              |                           | 0.02  |
| URTI                  | 2.0 (1.0, 2.0) | 1.0 (0.75, 2.0)             |                           | 0.7   |
| LRTI                  | 2.0 (1.0, 2.0) | 2.0 (1.0, 2.0)              |                           | 0.9   |
| U&LRTI                | 2.0 (1.0, 2.0) | 0.0 (0.0, 1.5)              |                           | 0.2   |

*$^*$Test of significance is the Wilcoxon signed rank test.

**Table 2**

Diagnostic accuracy of the clinical screening scores compared with combined viral immunofluorescence and polymerase chain reaction results in nose and throat swab samples collected from all hematopoietic stem cell transplant (HSCT) recipients, and during admission HSCT was received

| Laboratory testing | % (95% CI) | % (95% CI) | Likelihood ratio positive test | Likelihood ratio negative test | Positive predictive value | Negative predictive value |
|--------------------|------------|------------|--------------------------------|-------------------------------|---------------------------|---------------------------|
| Threshold          | Positive N | Negative N | Sensitivity | Specificity | Prevalence |                          |                          |
| HSCT recipients ($n=184$) | 21.7% |          |            |            |           |                          |                          |
| Score $\geq 1$     | 34         | 94         | 85.0       | 34.7       | 1.30      | 0.43                      | 26.6                     | 89.3                      |
| Score $<1$         | 6          | 50         | (70.2–94.3)| (27.0–43.1)| (1.09–1.55)| (0.20–0.93)                | (19.2–35.1)              | (78.1–96.0)               |
| Score $\geq 2$     | 25         | 62         | 62.5       | 56.9       | 1.45      | 0.66                      | 28.7                     | 84.5                      |
| Score $<2$         | 15         | 82         | (45.8–77.3)| (48.4–65.2)| (1.07–1.97)| (0.43–1.01)                | (19.5–39.4)              | (75.8–91.1)               |
| Patients during admission HSCT was received ($n=174$) | 13.5% |          |            |            |           |                          |                          |
| Score $\geq 1$     | 15         | 72         | 83.3       | 37.4       | 1.33      | 0.45                      | 17.2                     | 93.5                      |
| Score $<1$         | 3          | 43         | (58.6–96.4)| (28.6–46.9)| (1.04–1.71)| (0.15–1.29)                | (10.0–26.8)              | (82.1–98.6)               |
| Score $\geq 2$     | 10         | 47         | 55.6       | 59.1       | 1.36      | 0.75                      | 17.5                     | 89.5                      |
| Score $<2$         | 8          | 68         | (30.8–78.5)| (49.6–68.2)| (0.85–2.17)| (0.44–1.29)                | (8.8–29.9)               | (80.3–95.3)               |

CI, confidence interval.

**Table 3**
performed best at excluding RV infection with a threshold score of 1 symptom or sign at the given prevalences with an NPV of 89% (78–96%). Fewer samples were collected at a threshold of 1, and verification bias may have skewed these results. It should be noted that the screening tool quantified the number of characteristics, rather than gave weighting to specific symptoms or signs, in order to detect a variety of RVs that may have different clinical features and severity. Weighting of specific clinical features may improve the performance of the CS tool; this could not be further assessed in this study.

The likelihood ratios for scores above and below the screening thresholds corresponded with small, but potentially important, changes in the post-test probability of infection (20). The CS tool did not exclude infection when prevalence rates were high. In an outbreak setting with a potential prevalence of 50%, testing and infection control measures are warranted in all patients.

This study, which was designed to evaluate the CS tool in a working clinical context, revealed a significant limitation, namely, the low compliance observed with the screening tool. A score was recorded with only 36% of all respiratory samples collected and in half of these the score exceeded 2. Although the majority of all samples were taken without a logged score, NTS sampling increased 4-fold following the introduction of the screening tool, with RV detection in 25% of samples without a logged score during episodes of RTI. This is comparable with viral detection from samples scoring ≥ 2 and may suggest that CS was performed but scores were not recorded.

For practical reasons, paired NTS was chosen as the sample for diagnostic testing rather than nasopharyngeal aspiration (NPA). While NPA obtains the highest viral burden from the URT (21), paired NTS have a sensitivity equivalent to NPA in children (22). While this may not be the case in adults, owing to lower viral loads (23), sensitive molecular methods were used to optimize RV detection. NTS cause less pain than NPA in children (24) and adults (25, 26). NTS were used in this study because of their greater tolerability in adults (especially HSCT recipients who may have complicating factors such as mucositis), particularly as multiple specimens were collected from each patient. Additional benefits of NTS include greater ease of collection by nurses, and consequent earlier collection than with NPA, which requires additional equipment and expertise (24). RVs were detected in a greater proportion of NTS during episodes of URTI than LRTI. As URT specimens are less sensitive for RV detection than BAL during LRTI (27), it remains essential to consider BAL in the absence of a positive RV in this setting (7).

Based on our data, molecular methods of identification should be included in a diagnostic algorithm to detect clinically important RVs in addition to IF and viral culture. We noted 23% of PCR-positive RVs were also positive by IF. While PCR can detect 15 individual viruses and IF only 7 of these, IF was positive for only 45% of the 7 viruses positive by PCR. The superior performance of PCR for these 7 viruses is well known, with sensitivity of IF in symptomatic children of 63–70% (28). IF for ADV is known to be insensitive (15–30% in symptomatic children [28]), and 0 of 10 PCR-positive samples in the current study were detected by IF. In adult HSCT recipients, the poor sensitivity of IF compared with combined IF, PCR, and viral culture in nasal wash specimens has been documented previously for influenza (1/3 samples), RSV (3/6), and PIV (2/18) (29). We have confirmed these results with a larger sample and

Table 4

| Pre-test probability (prevalence) | Post-test probability | Number needed to test for positive result | Post-test probability | Number needed to test for positive result | Post-test probability | Number needed to test for positive result | Post-test probability | Number needed to test for positive result |
|----------------------------------|-----------------------|------------------------------------------|-----------------------|------------------------------------------|-----------------------|------------------------------------------|-----------------------|------------------------------------------|
| 22%                              | 26 (23–30)            | 3.8 (3.3–4.3)                            | 11 (5–20)             | 9.1 (5–20)                              | 29 (23–35)            | 3.4 (2.9–4.3)                            | 15 (11–22)            | 6.4 (5.9–9.1)                            |
| 10%                              | 13 (12–14)            | 7.7 (7.1–8.3)                            | 5 (3–7)               | 20 (14.3–33.3)                         | 14 (12–16)            | 7.1 (6.3–8.3)                            | 7 (5–9)               | 14 (12–16)                              |
| 35%                              | 41 (39–43)            | 2.4 (2.3–2.6)                            | 19 (15–23)            | 5.3 (4.3–6.7)                           | 44 (41–47)            | 2.3 (2.1–2.4)                            | 26 (23–29)            | 3.8 (3.4–4.3)                            |
| 50%                              | 57 (55–58)            | 1.8 (1.7–1.8)                            | 30 (25–35)            | 3.3 (2.9–4)                            | 59 (56–62)            | 1.7 (1.6–1.8)                            | 40 (37–43)            | 2.5 (2.3–2.7)                            |

CI, confidence interval.
### Diagnostic accuracy of immunofluorescence (IF) testing compared with polymerase chain reaction (PCR) by respiratory virus tested, those detectable by IF, and any positive result (all available samples, n = 1035)

| IF                        | PCR   | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) |
|---------------------------|-------|------------|------------|------------|------------|
|                           | IF    | Positive   | Negative   | Sensitivity| Specificity|
| Influenza A               | Positive | 13         | 11         | 65.0       | 98.9       |
|                           | Negative| 7          | 1004       | 40.8–84.6  | 98.1–99.5  |
| Influenza B               | Positive| 2          | 2          | 40.0       | 99.8       |
|                           | Negative| 3          | 1028       | 5.3–85.3   | 99.3–99.9  |
| RSV                      | Positive| 6          | 18         | 75.0       | 98.3       |
|                           | Negative| 2          | 1009       | 349–96.8   | 97.2–99.0  |
| Adenovirus                | Positive| 0          | 0          | NA         | 99.0       |
|                           | Negative| 10        | 1025       | (98.2–99.5)| NA         |
| PIV1                      | Positive| 7          | 0          | 46.7       | NA         |
|                           | Negative| 8          | 1020       | (21.3–73.4)| (98.5–99.7)|
| PIV3                      | Positive| 2          | 1          | 20.0       | 99.9       |
|                           | Negative| 8          | 1024       | (2.5–55.6) | (99.5–99.9)|
| hMPV                      | Positive| 4          | 0          | NA         | NA         |
|                           | Negative| 0          | 1031       | NA         | NA         |
| Influenza A and B, RSV, PIV, and adenovirus (viruses detectable by IF) | Positive | 31         | 35         | 44.9       | 96.4       |
| Detection of any respiratory virus | Positive | 35         | 31         | 22.6       | 96.5       |
|                           | Negative| 120        | 849        | (163–30.0) | (95.0–97.6)|

CI, confidence interval; RSV, respiratory syncytial virus; PIV, parainfluenza virus; hMPV, human metapneumovirus; NA, not applicable.
Acknowledgements:

The authors acknowledge Mala Ratnamohan, Ken McPhie, Sue Alderson, Gordana Nedeljkovic, Beverly Horne, and Terry Flood from the Respiratory Virology Laboratory at CIDMLS; laboratory staff at QPID; and staff and patients from the hematology ward, Westmead Hospital.

Financial support: This study was supported by grants from The National Health and Medical Research Council, Department of Health and Ageing, Australian Government to The NHMRC Clinical Centre for Research Excellence in Bioethics and Haematological Malignancies (Grant 264625); New South Wales Department of Health Capacity Building Infrastructure Grant 2003/04–2005/06; New South Wales Department of Health Capacity Building Infrastructure Grant 2006/07–2008/09; and a National Health and Medical Research Council of Australia postgraduate medical scholarship to P. E. F.

Conflict of interest: All authors report no conflicts of interest relevant to this article.

References

1. Jalal H, Bibby DF, Bennett J, et al. Molecular investigations of an outbreak of parainfluenza virus type 3 and respiratory syncytial virus infections in a hematology unit. J Clin Microbiol 2007; 45 (6): 1690–1696.
2. Abdallah A, Rowland KE, Schepetiuk SK, To LB, Bardy P. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant 2003; 32 (2): 195–203.
3. Zambon M, Bull T, Sadler CJ, Goldman JM, Ward KN. Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. J Clin Microbiol 1998; 36 (8): 2289–2293.
4. Cortez KJ, Erdman DD, Peret TC, et al. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplantation population. J Infect Dis 2003; 184 (9): 1090–1097.
5. McCann S, Byrne JL, Rovira M, et al. Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 2004; 33 (5): 519–529.
6. Dykewicz CA, National Center for Infectious Diseases, Center for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transplant 2001; 7: 195–228.
7. Tombreyn M, ChillerT, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15 (10): 1143–1238.
8. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28 (5): 479–484.
9. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant 2003; 32: 73–77.
10. Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 2003; 31 (8): 695–700.
11. Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11: 781–796.
12. Syrimis MW, Whiley DM, Thomas M, et al. A sensitive, specific, and cost-effective multiplex reverse transcriptase-PCR assay for the detection of seven common respiratory viruses in respiratory samples. J Mol Diagn 2004; 6 (2): 125–131.
13. Maertzdorf A, Wang CK, Brown JB, et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol 2004; 42 (3): 981–986.
14. Arden KE, McErlean P, Nissen MD, Sloots TP, Mackay IM. Frequent detection of human rhinoviruses, paramyxoviruses, coronaviruses, and bocavirus during acute respiratory tract infections. J Med Virol 2006; 78 (9): 1232–1240.
15. Sloots TP, McErlean P, Speicher DJ, Arden KE, Nissen MD, Mackay IM. Evidence of human coronavirus HKU1 and human bocavirus in Australian children. J Clin Virol 2006; 35 (1): 99–102.
16. Gaynor AM, Nissen MD, Whiley DM, et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathogens 2007; 3 (5): e64.
17. Bialasiewicz S, Whiley DM, Lambert SB, Gould A, Nissen MD, Sloots TP. Development and evaluation of real-time PCR assays for the detection of the newly identified KI and WU polyomaviruses. J Clin Virol 2007; 40 (1): 9–14.
18. Bialasiewicz S, Whiley DM, Lambert SB, et al. Presence of the newly discovered human polyomaviruses KI and WU in Australian patients with acute respiratory tract infection. J Clin Virol 2008; 41 (2): 63–68.
19. Mackinnon A. A spreadsheet for the calculation of comprehensive statistics for the assessment of diagnostic tests and inter-rater agreement. Comput Biol Med 2000; 30 (3): 127–134.
20. Jaeschke R, Guyatt GH, Sackett DL. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994; 271 (9): 703–707.
21. Chan KH, Maldeis N, Pope W, et al. Evaluation of the Directigen Flu A + B test for rapid diagnosis of influenza virus type A and B infections. J Clin Microbiol 2002; 40 (5): 1675–1680.
22. Heikkinen T, Salmi AA, Ruuskanen O. Comparative study of nasopharyngeal aspirate and nasal swab specimens for detection of influenza. Br Med J 2001; 322 (7279): 138.
23. Englund JA, Piedra PA, Jewell A, Patel K, Baxter BB, Whimbey E. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol 1996; 34 (7): 1649–1653.
24. Macfarlane P, Denham J, Assous J, Hughes C. RSV testing in bronchiolitis which nasal sampling method is best? Arch Dis Childhood 2005; 90 (6): 634–635.
25. Gavin PJ, Thomson RB Jr. Review of rapid diagnostic tests for influenza. Clin Appl Immunol Rev 2003; 4: 151–172.
26. Heikkinen T, Marttila J, Salmi A, et al. Nasal swab versus nasopharyngeal aspirate for isolation of respiratory viruses. J Clin Microbiol 2002; 40 (11): 4337–4339.
27. Blyth CC, Iredell JR, Dwyer DE. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 361 (25): 2493.
28. Kuypers J, Wright N, Ferrenberg J, et al. Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. J Clin Virol 2006; 44 (7): 2382–2388.
29. Kuypers J, Campbell AP, Gent A, Corey L, Boeckh M. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis 2009; 11 (4): 298–303.
30. Brittain-Long R, Nord S, Olofsson S, Westin J, Anderson L-M, Lindh M. Multiplex real-time PCR for detection of respiratory tract infection. J Clin Virol 2008; 41: 53–56.